MGC Pharma ready to commence registration of dermatological products
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
MGC Pharmaceuticals (ASX:MXC) announced on Monday morning that the company had completed its safety assessment in relation to its cannabidiol (CBD) based dermatological treatment products for symptoms of acne, psoriasis and seborrhoea.
This is an important development for the company as it paves the way for the group to commence registration of these products with the European Cosmetic Products Notification Portal (CPNP), which once ratified will enable MXC to distribute its products throughout the European Union.
Safety assessment included skin patch tests on 30 human volunteers, and the results delivered a 100% success rate. The company will shortly commence three-month clinical tests on human volunteers in Slovenia to determine the efficacy of the products.
In highlighting the importance of this development, co-founder and Managing Director of MXC, Nativ Segev said, “The commencement of our registration with the European Cosmetics Production Notification Portal is a significant milestone in the company’s journey towards commercialisation, as certification will then allow MGC Pharmaceuticals to immediately sell its CBD dermatological skincare products throughout the European Union”.
Upcoming clinical tests
Segev also highlighted the fact that it was encouraging to be making the progression to clinical tests of the group’s CBD dermatological products in order to demonstrate the efficacy of its formulations.
MXC expects to commence a three month testing phase shortly on human volunteers across its three CBD based dermatological products.
While Segev did not put a timeline on when results are likely to come to hand, a favourable outcome could provide positive share price momentum.
However, this is an early stage stock and investors should note that forward-looking statements and potential share price movements should not form the basis for an investment decision and if considering this stock independent financial advice should be sought.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.